How much did Incyte achieve in EBIT for the current year?
In the current year, Incyte has achieved an EBIT of 376.92 M USD.
Incyte EBIT 2024
Incyte EBIT
376.92 M USD
Ticker
INCY
ISIN
US45337C1027
WKN
896133
In 2024, Incyte's EBIT was 376.92 M USD, a -42.17% increase from the 651.77 M USD EBIT recorded in the previous year.
The Incyte EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | 0.84 |
| 2028e | 2.18 |
| 2027e | 2.01 |
| 2026e | 1.86 |
| 2025e | 1.45 |
| 2024e | 0.38 |
| 2023 | 0.65 |
| 2022 | 0.6 |
| 2021 | 0.64 |
| 2020 | -0.2 |
| 2019 | 0.42 |
| 2018 | 0.16 |
| 2017 | -0.24 |
| 2016 | 0.16 |
| 2015 | 0.05 |
| 2014 | -0 |
| 2013 | -0.02 |
| 2012 | 0 |
| 2011 | -0.14 |
| 2010 | 0.01 |
| 2009 | -0.14 |
| 2008 | -0.16 |
| 2007 | -0.09 |
| 2006 | -0.08 |
| 2005 | -0.1 |
| 2004 | -0.15 |
Incyte Revenue, EBIT, Net Income US45337C1027 · 896133
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Incyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Incyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Incyte’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Incyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Incyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Incyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Incyte’s growth potential.
Incyte Revenue, EBIT and net profit per share
| Date | Incyte Revenue | Incyte EBIT | Incyte Net Income |
|---|---|---|---|
| 2029e | 4.07 B undefined | 838.19 M undefined | 882.02 M undefined |
| 2028e | 6.02 B undefined | 2.18 B undefined | 1.98 B undefined |
| 2027e | 5.68 B undefined | 2.01 B undefined | 1.77 B undefined |
| 2026e | 5.24 B undefined | 1.86 B undefined | 1.52 B undefined |
| 2025e | 4.73 B undefined | 1.45 B undefined | 1.21 B undefined |
| 2024e | 4.29 B undefined | 376.92 M undefined | 256.6 M undefined |
| 2023 | 3.7 B undefined | 651.77 M undefined | 597.6 M undefined |
| 2022 | 3.39 B undefined | 599.5 M undefined | 340.7 M undefined |
| 2021 | 2.99 B undefined | 637.6 M undefined | 948.6 M undefined |
| 2020 | 2.67 B undefined | -197.5 M undefined | -295.7 M undefined |
| 2019 | 2.16 B undefined | 421.7 M undefined | 446.9 M undefined |
| 2018 | 1.88 B undefined | 155.4 M undefined | 109.5 M undefined |
| 2017 | 1.54 B undefined | -235.7 M undefined | -313.1 M undefined |
| 2016 | 1.11 B undefined | 162.4 M undefined | 104.2 M undefined |
| 2015 | 753.8 M undefined | 50.7 M undefined | 6.5 M undefined |
| 2014 | 511.5 M undefined | -4.8 M undefined | -48.5 M undefined |
| 2013 | 354.9 M undefined | -16.1 M undefined | -83.1 M undefined |
| 2012 | 297.1 M undefined | 1.1 M undefined | -44.3 M undefined |
| 2011 | 94.5 M undefined | -142.5 M undefined | -186.5 M undefined |
| 2010 | 169.9 M undefined | 13.7 M undefined | -31.8 M undefined |
| 2009 | 9.3 M undefined | -137.8 M undefined | -211.9 M undefined |
| 2008 | 3.9 M undefined | -159.5 M undefined | -178.9 M undefined |
| 2007 | 34.4 M undefined | -85.7 M undefined | -86.9 M undefined |
| 2006 | 27.6 M undefined | -76.9 M undefined | -74.2 M undefined |
| 2005 | 7.8 M undefined | -99.4 M undefined | -103 M undefined |
| 2004 | 14.1 M undefined | -148.9 M undefined | -164.8 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 14.1 M USD | -148.9 M USD | -164.8 M USD |
| 2005 | 7.8 M USD | -99.4 M USD | -103 M USD |
| 2006 | 27.6 M USD | -76.9 M USD | -74.2 M USD |
| 2007 | 34.4 M USD | -85.7 M USD | -86.9 M USD |
| 2008 | 3.9 M USD | -159.5 M USD | -178.9 M USD |
| 2009 | 9.3 M USD | -137.8 M USD | -211.9 M USD |
| 2010 | 169.9 M USD | 13.7 M USD | -31.8 M USD |
| 2011 | 94.5 M USD | -142.5 M USD | -186.5 M USD |
| 2012 | 297.1 M USD | 1.1 M USD | -44.3 M USD |
| 2013 | 354.9 M USD | -16.1 M USD | -83.1 M USD |
| 2014 | 511.5 M USD | -4.8 M USD | -48.5 M USD |
| 2015 | 753.8 M USD | 50.7 M USD | 6.5 M USD |
| 2016 | 1.11 B USD | 162.4 M USD | 104.2 M USD |
| 2017 | 1.54 B USD | -235.7 M USD | -313.1 M USD |
| 2018 | 1.88 B USD | 155.4 M USD | 109.5 M USD |
| 2019 | 2.16 B USD | 421.7 M USD | 446.9 M USD |
| 2020 | 2.67 B USD | -197.5 M USD | -295.7 M USD |
| 2021 | 2.99 B USD | 637.6 M USD | 948.6 M USD |
| 2022 | 3.39 B USD | 599.5 M USD | 340.7 M USD |
| 2023 | 3.7 B USD | 651.77 M USD | 597.6 M USD |
| 2024e | 4.29 B USD | 376.92 M USD | 256.6 M USD |
| 2025e | 4.73 B USD | 1.45 B USD | 1.21 B USD |
| 2026e | 5.24 B USD | 1.86 B USD | 1.52 B USD |
| 2027e | 5.68 B USD | 2.01 B USD | 1.77 B USD |
| 2028e | 6.02 B USD | 2.18 B USD | 1.98 B USD |
| 2029e | 4.07 B USD | 838.19 M USD | 882.02 M USD |
Incyte stock margins US45337C1027 · 896133
The Incyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Incyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Incyte.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Incyte's sales revenue. A higher gross margin percentage indicates that the Incyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Incyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Incyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Incyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Incyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Incyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Incyte Margin History
| Incyte Gross margin | Incyte Profit margin | Incyte EBIT margin | Incyte Profit margin |
|---|---|---|---|
| 2029e | 93.71 % | 20.62 % | 21.7 % |
| 2028e | 93.71 % | 36.25 % | 32.94 % |
| 2027e | 93.71 % | 35.33 % | 31.16 % |
| 2026e | 93.71 % | 35.58 % | 29.04 % |
| 2025e | 93.71 % | 30.71 % | 25.5 % |
| 2024e | 93.71 % | 8.79 % | 5.98 % |
| 2023 | 93.71 % | 17.64 % | 16.17 % |
| 2022 | 94.54 % | 17.66 % | 10.04 % |
| 2021 | 95.66 % | 21.35 % | 31.77 % |
| 2020 | 95.88 % | -7.41 % | -11.09 % |
| 2019 | 95.7 % | 19.53 % | 20.7 % |
| 2018 | 96.14 % | 8.26 % | 5.82 % |
| 2017 | 96.22 % | -15.34 % | -20.38 % |
| 2016 | 95.88 % | 14.69 % | 9.42 % |
| 2015 | 96.42 % | 6.73 % | 0.86 % |
| 2014 | 99.41 % | -0.94 % | -9.48 % |
| 2013 | 99.83 % | -4.54 % | -23.42 % |
| 2012 | 99.93 % | 0.37 % | -14.91 % |
| 2011 | 93.71 % | -150.79 % | -197.35 % |
| 2010 | 93.71 % | 8.06 % | -18.72 % |
| 2009 | 93.71 % | -1,481.72 % | -2,278.49 % |
| 2008 | 93.71 % | -4,089.74 % | -4,587.18 % |
| 2007 | 93.71 % | -249.13 % | -252.62 % |
| 2006 | 93.71 % | -278.62 % | -268.84 % |
| 2005 | 93.71 % | -1,274.36 % | -1,320.51 % |
| 2004 | 93.71 % | -1,056.03 % | -1,168.79 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 93.71 % | -1,056.03 % | -1,168.79 % |
| 2005 | 93.71 % | -1,274.36 % | -1,320.51 % |
| 2006 | 93.71 % | -278.62 % | -268.84 % |
| 2007 | 93.71 % | -249.13 % | -252.62 % |
| 2008 | 93.71 % | -4,089.74 % | -4,587.18 % |
| 2009 | 93.71 % | -1,481.72 % | -2,278.49 % |
| 2010 | 93.71 % | 8.06 % | -18.72 % |
| 2011 | 93.71 % | -150.79 % | -197.35 % |
| 2012 | 99.93 % | 0.37 % | -14.91 % |
| 2013 | 99.83 % | -4.54 % | -23.42 % |
| 2014 | 99.41 % | -0.94 % | -9.48 % |
| 2015 | 96.42 % | 6.73 % | 0.86 % |
| 2016 | 95.88 % | 14.69 % | 9.42 % |
| 2017 | 96.22 % | -15.34 % | -20.38 % |
| 2018 | 96.14 % | 8.26 % | 5.82 % |
| 2019 | 95.7 % | 19.53 % | 20.7 % |
| 2020 | 95.88 % | -7.41 % | -11.09 % |
| 2021 | 95.66 % | 21.35 % | 31.77 % |
| 2022 | 94.54 % | 17.66 % | 10.04 % |
| 2023 | 93.71 % | 17.64 % | 16.17 % |
| 2024e | 93.71 % | 8.79 % | 5.98 % |
| 2025e | 93.71 % | 30.71 % | 25.5 % |
| 2026e | 93.71 % | 35.58 % | 29.04 % |
| 2027e | 93.71 % | 35.33 % | 31.16 % |
| 2028e | 93.71 % | 36.25 % | 32.94 % |
| 2029e | 93.71 % | 20.62 % | 21.7 % |
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
82 % Product
14 % Product Royalty
4 % Milestone & Contract
EBIT Details
Analyzing Incyte's EBIT
Incyte's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Incyte's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Incyte's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Incyte’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Incyte stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Incyte.
How has the EBIT of Incyte developed in recent years?
The EBIT of Incyte has increased by -42.17% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Incyte?
The EBIT of Incyte is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
